Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/93949 
Year of Publication: 
2006
Series/Report no.: 
SFB/TR 15 Discussion Paper No. 189
Publisher: 
Sonderforschungsbereich/Transregio 15 - Governance and the Efficiency of Economic Systems (GESY), München
Abstract: 
The efficient allocation of control rights in inter-firm collaborations is a widely emphasized issue. In this paper, I empirically identify control rights and the allocation of these rights using a unique survey data set on collaborations between biotechnology and pharmaceutical firms. Fifteen control rights are identified to make up the structure of deals with five rights being the items of contention in deal making (ownership of patents, production, further development of the technology, the right to manage the collaboration, and the right to market universally). I find that the assignment of control rights is related to the bargaining position of firms and incentive issues. Hence, goliaths -pharmaceutical incumbents- subrogate critical rights to the new ventures when the final outcome of the project is depending on the venture's effort.
Subjects: 
contracts
performance
inter-firm collaboration
biotechnology
JEL: 
D23
L24
G30
M13
O32
Persistent Identifier of the first edition: 
Document Type: 
Working Paper

Files in This Item:
File
Size





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.